Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-11-20

AUTHORS

Tanya B. Dorff, Denice Tsao-Wei, Gus Miranda, Donald G. Skinner, John P. Stein, David I. Quinn

ABSTRACT

ObjectivesTo describe the tolerability of two chemotherapy regimens, gemcitabine and cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for adjuvant treatment of patients with locally advanced urothelial cancer after radical cystectomy.MethodsThe USC Department of Urology bladder cancer database was searched for subjects who received adjuvant chemotherapy following cystectomy for transitional cell carcinoma with extravesical and/or lymph node involvement, yielding 187 cases. Clinical details regarding toxicity, number of cycles administered, and cancer outcome were analyzed.ResultsThe majority of subjects had lymph node involvement (70%). Sixty-eight percent of subjects received MVAC and 32% received GC, the latter regimen was predominant after 2000. Fifty-six percent of subjects received all four planned cycles (51% GC and 58% MVAC). With a median follow-up of 11.2 years (range 1.9–19.6), 96 patients (51%) have suffered a relapse, with no significant difference between chemotherapy regimens. Median time to recurrence for the population was 3.7 years and median overall survival is 4.6 years (3.0–9.3). The median time from recurrence to death was 6.7 months and was not significantly different between MVAC and GC.ConclusionsBoth MVAC and GC are tolerated after cystectomy for advanced urothelial carcinoma. A significant proportion of high-risk patients survive, free of disease, beyond 10 years. At recurrence, patients previously treated with adjuvant chemotherapy have a survival that appears much shorter than patients who develop metastases in the absence of this exposure, suggesting resistance to salvage chemotherapy. More... »

PAGES

39-44

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00345-008-0342-4

DOI

http://dx.doi.org/10.1007/s00345-008-0342-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021499032

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19020886


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "California", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Transitional Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Feasibility Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methotrexate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Universities", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urinary Bladder Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vinblastine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA", 
            "USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dorff", 
        "givenName": "Tanya B.", 
        "id": "sg:person.01007666002.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007666002.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsao-Wei", 
        "givenName": "Denice", 
        "id": "sg:person.010304735667.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010304735667.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miranda", 
        "givenName": "Gus", 
        "id": "sg:person.0632606342.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632606342.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Skinner", 
        "givenName": "Donald G.", 
        "id": "sg:person.0770566644.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770566644.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stein", 
        "givenName": "John P.", 
        "id": "sg:person.0757510711.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757510711.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "David I.", 
        "id": "sg:person.01013134010.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2008-11-20", 
    "datePublishedReg": "2008-11-20", 
    "description": "ObjectivesTo describe the tolerability of two chemotherapy regimens, gemcitabine and cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for adjuvant treatment of patients with locally advanced urothelial cancer after radical cystectomy.MethodsThe USC Department of Urology bladder cancer database was searched for subjects who received adjuvant chemotherapy following cystectomy for transitional cell carcinoma with extravesical and/or lymph node involvement, yielding 187 cases. Clinical details regarding toxicity, number of cycles administered, and cancer outcome were analyzed.ResultsThe majority of subjects had lymph node involvement (70%). Sixty-eight percent of subjects received MVAC and 32% received GC, the latter regimen was predominant after 2000. Fifty-six percent of subjects received all four planned cycles (51% GC and 58% MVAC). With a median follow-up of 11.2\u00a0years (range 1.9\u201319.6), 96 patients (51%) have suffered a relapse, with no significant difference between chemotherapy regimens. Median time to recurrence for the population was 3.7\u00a0years and median overall survival is 4.6\u00a0years (3.0\u20139.3). The median time from recurrence to death was 6.7\u00a0months and was not significantly different between MVAC and GC.ConclusionsBoth MVAC and GC are tolerated after cystectomy for advanced urothelial carcinoma. A significant proportion of high-risk patients survive, free of disease, beyond 10\u00a0years. At recurrence, patients previously treated with adjuvant chemotherapy have a survival that appears much shorter than patients who develop metastases in the absence of this exposure, suggesting resistance to salvage chemotherapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00345-008-0342-4", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094127", 
        "issn": [
          "0724-4983", 
          "1433-8726"
        ], 
        "name": "World Journal of Urology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "keywords": [
      "advanced urothelial carcinoma", 
      "lymph node involvement", 
      "percent of subjects", 
      "adjuvant chemotherapy", 
      "node involvement", 
      "median time", 
      "urothelial carcinoma", 
      "advanced urothelial cancer", 
      "median overall survival", 
      "high-risk patients", 
      "bladder cancer database", 
      "transitional cell carcinoma", 
      "majority of subjects", 
      "chemotherapy regimens", 
      "adjuvant treatment", 
      "overall survival", 
      "radical cystectomy", 
      "urothelial cancer", 
      "latter regimen", 
      "cell carcinoma", 
      "cancer outcomes", 
      "clinical details", 
      "Cancer Database", 
      "chemotherapy", 
      "patients", 
      "USC Experience", 
      "cystectomy", 
      "carcinoma", 
      "MVAC", 
      "significant differences", 
      "recurrence", 
      "significant proportion", 
      "cisplatin", 
      "subjects", 
      "survival", 
      "years", 
      "involvement", 
      "tolerability", 
      "percent", 
      "regimens", 
      "regimen", 
      "gemcitabine", 
      "relapse", 
      "metastasis", 
      "cancer", 
      "ObjectivesTo", 
      "disease", 
      "months", 
      "death", 
      "vinblastine", 
      "outcomes", 
      "doxorubicin", 
      "treatment", 
      "toxicity", 
      "exposure", 
      "Department", 
      "majority", 
      "population", 
      "proportion", 
      "GC", 
      "differences", 
      "absence", 
      "database", 
      "cases", 
      "time", 
      "resistance", 
      "experience", 
      "cycle", 
      "number", 
      "overview", 
      "number of cycles", 
      "detail"
    ], 
    "name": "Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience", 
    "pagination": "39-44", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021499032"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00345-008-0342-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19020886"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00345-008-0342-4", 
      "https://app.dimensions.ai/details/publication/pub.1021499032"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_461.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00345-008-0342-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00345-008-0342-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00345-008-0342-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00345-008-0342-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00345-008-0342-4'


 

This table displays all metadata directly associated to this object as RDF triples.

254 TRIPLES      20 PREDICATES      118 URIs      110 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00345-008-0342-4 schema:about N0d47ff676a4544c3b62ba2d3ef16fe2c
2 N1d1ce7fe9586468cb99d0c445f49c290
3 N23f5eedd2f8d4af8a84612164bafd59d
4 N432d9fd5040d4c1b96609a8e4849ef67
5 N5346f55ae22c43e99a0f2791640b0441
6 N69e12fcc9d534cf6bd98b9353f4dee12
7 N6bf39f7b80314af7a0918b27b630bf88
8 N6ebf195f0d6447c6ba55f3b324f37a8e
9 N72cfcaeca8d54008ab1616365580dd0b
10 N73221e71648d4c40ac9195fb9c35581e
11 N7525a102f8004bab87238261ac576f00
12 N789d5237bb464c57abb99f3a1f997008
13 N7af21a11b9b24da884b2215854c9b74d
14 N805e60d124b44d4eb0638e92a39ee11e
15 Na2a1fc77e2c649639b95af1c5455f8bb
16 Nbe2dfabec6be4afc98830d558a65ed36
17 Nd2580fd003c9421d8f14d7963e4c01e9
18 Nd70a8222416044f7800b1a957f7c31e9
19 Nd8e3abd3a9aa4466b64244587b432032
20 Ne043f5de4d454aadbdd4fe475740f724
21 Ned24ed99e52b4151878d193973753bce
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author Nb4f2a1ca77784fe2a6549988b634e2eb
25 schema:datePublished 2008-11-20
26 schema:datePublishedReg 2008-11-20
27 schema:description ObjectivesTo describe the tolerability of two chemotherapy regimens, gemcitabine and cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for adjuvant treatment of patients with locally advanced urothelial cancer after radical cystectomy.MethodsThe USC Department of Urology bladder cancer database was searched for subjects who received adjuvant chemotherapy following cystectomy for transitional cell carcinoma with extravesical and/or lymph node involvement, yielding 187 cases. Clinical details regarding toxicity, number of cycles administered, and cancer outcome were analyzed.ResultsThe majority of subjects had lymph node involvement (70%). Sixty-eight percent of subjects received MVAC and 32% received GC, the latter regimen was predominant after 2000. Fifty-six percent of subjects received all four planned cycles (51% GC and 58% MVAC). With a median follow-up of 11.2 years (range 1.9–19.6), 96 patients (51%) have suffered a relapse, with no significant difference between chemotherapy regimens. Median time to recurrence for the population was 3.7 years and median overall survival is 4.6 years (3.0–9.3). The median time from recurrence to death was 6.7 months and was not significantly different between MVAC and GC.ConclusionsBoth MVAC and GC are tolerated after cystectomy for advanced urothelial carcinoma. A significant proportion of high-risk patients survive, free of disease, beyond 10 years. At recurrence, patients previously treated with adjuvant chemotherapy have a survival that appears much shorter than patients who develop metastases in the absence of this exposure, suggesting resistance to salvage chemotherapy.
28 schema:genre article
29 schema:isAccessibleForFree false
30 schema:isPartOf N73aceb85ace045458e2ec8ed02ddd622
31 Nfffd1afa66b04608a0d53d61fbc18a0e
32 sg:journal.1094127
33 schema:keywords Cancer Database
34 Department
35 GC
36 MVAC
37 ObjectivesTo
38 USC Experience
39 absence
40 adjuvant chemotherapy
41 adjuvant treatment
42 advanced urothelial cancer
43 advanced urothelial carcinoma
44 bladder cancer database
45 cancer
46 cancer outcomes
47 carcinoma
48 cases
49 cell carcinoma
50 chemotherapy
51 chemotherapy regimens
52 cisplatin
53 clinical details
54 cycle
55 cystectomy
56 database
57 death
58 detail
59 differences
60 disease
61 doxorubicin
62 experience
63 exposure
64 gemcitabine
65 high-risk patients
66 involvement
67 latter regimen
68 lymph node involvement
69 majority
70 majority of subjects
71 median overall survival
72 median time
73 metastasis
74 months
75 node involvement
76 number
77 number of cycles
78 outcomes
79 overall survival
80 overview
81 patients
82 percent
83 percent of subjects
84 population
85 proportion
86 radical cystectomy
87 recurrence
88 regimen
89 regimens
90 relapse
91 resistance
92 significant differences
93 significant proportion
94 subjects
95 survival
96 time
97 tolerability
98 toxicity
99 transitional cell carcinoma
100 treatment
101 urothelial cancer
102 urothelial carcinoma
103 vinblastine
104 years
105 schema:name Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience
106 schema:pagination 39-44
107 schema:productId N10a813f423164d9baea9beb3ccad9b67
108 N419b6f75ef8740f69635445167882ae2
109 Ndc1f8b1ff793458595b7a3b0cf31dc7c
110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021499032
111 https://doi.org/10.1007/s00345-008-0342-4
112 schema:sdDatePublished 2022-09-02T15:52
113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
114 schema:sdPublisher Nfa5a204a59d04c0897d5b61f3e3bd12f
115 schema:url https://doi.org/10.1007/s00345-008-0342-4
116 sgo:license sg:explorer/license/
117 sgo:sdDataset articles
118 rdf:type schema:ScholarlyArticle
119 N0d47ff676a4544c3b62ba2d3ef16fe2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Methotrexate
121 rdf:type schema:DefinedTerm
122 N10a813f423164d9baea9beb3ccad9b67 schema:name pubmed_id
123 schema:value 19020886
124 rdf:type schema:PropertyValue
125 N1a4f3979ae874ea58511335464171e19 rdf:first sg:person.0757510711.79
126 rdf:rest N8ea3b83165674bf09d837ba6ee6a78d3
127 N1d1ce7fe9586468cb99d0c445f49c290 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Disease Progression
129 rdf:type schema:DefinedTerm
130 N23f5eedd2f8d4af8a84612164bafd59d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Aged
132 rdf:type schema:DefinedTerm
133 N419b6f75ef8740f69635445167882ae2 schema:name dimensions_id
134 schema:value pub.1021499032
135 rdf:type schema:PropertyValue
136 N432d9fd5040d4c1b96609a8e4849ef67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Middle Aged
138 rdf:type schema:DefinedTerm
139 N5346f55ae22c43e99a0f2791640b0441 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Retrospective Studies
141 rdf:type schema:DefinedTerm
142 N5acdfd550fda40f48ccce71c47ee575c rdf:first sg:person.010304735667.62
143 rdf:rest N831c090a0755401991e3504f4c1a1b42
144 N69e12fcc9d534cf6bd98b9353f4dee12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 N6bf39f7b80314af7a0918b27b630bf88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Vinblastine
149 rdf:type schema:DefinedTerm
150 N6cd8409ec5d94b14ba9ea1f8250dad10 rdf:first sg:person.0770566644.20
151 rdf:rest N1a4f3979ae874ea58511335464171e19
152 N6ebf195f0d6447c6ba55f3b324f37a8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Urinary Bladder Neoplasms
154 rdf:type schema:DefinedTerm
155 N72cfcaeca8d54008ab1616365580dd0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Universities
157 rdf:type schema:DefinedTerm
158 N73221e71648d4c40ac9195fb9c35581e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Aged, 80 and over
160 rdf:type schema:DefinedTerm
161 N73aceb85ace045458e2ec8ed02ddd622 schema:issueNumber 1
162 rdf:type schema:PublicationIssue
163 N7525a102f8004bab87238261ac576f00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Chemotherapy, Adjuvant
165 rdf:type schema:DefinedTerm
166 N789d5237bb464c57abb99f3a1f997008 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name California
168 rdf:type schema:DefinedTerm
169 N7af21a11b9b24da884b2215854c9b74d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Female
171 rdf:type schema:DefinedTerm
172 N805e60d124b44d4eb0638e92a39ee11e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Adult
174 rdf:type schema:DefinedTerm
175 N831c090a0755401991e3504f4c1a1b42 rdf:first sg:person.0632606342.26
176 rdf:rest N6cd8409ec5d94b14ba9ea1f8250dad10
177 N8ea3b83165674bf09d837ba6ee6a78d3 rdf:first sg:person.01013134010.15
178 rdf:rest rdf:nil
179 Na2a1fc77e2c649639b95af1c5455f8bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Cisplatin
181 rdf:type schema:DefinedTerm
182 Nb4f2a1ca77784fe2a6549988b634e2eb rdf:first sg:person.01007666002.23
183 rdf:rest N5acdfd550fda40f48ccce71c47ee575c
184 Nbe2dfabec6be4afc98830d558a65ed36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Doxorubicin
186 rdf:type schema:DefinedTerm
187 Nd2580fd003c9421d8f14d7963e4c01e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Carcinoma, Transitional Cell
189 rdf:type schema:DefinedTerm
190 Nd70a8222416044f7800b1a957f7c31e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Male
192 rdf:type schema:DefinedTerm
193 Nd8e3abd3a9aa4466b64244587b432032 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Feasibility Studies
195 rdf:type schema:DefinedTerm
196 Ndc1f8b1ff793458595b7a3b0cf31dc7c schema:name doi
197 schema:value 10.1007/s00345-008-0342-4
198 rdf:type schema:PropertyValue
199 Ne043f5de4d454aadbdd4fe475740f724 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Antineoplastic Combined Chemotherapy Protocols
201 rdf:type schema:DefinedTerm
202 Ned24ed99e52b4151878d193973753bce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Deoxycytidine
204 rdf:type schema:DefinedTerm
205 Nfa5a204a59d04c0897d5b61f3e3bd12f schema:name Springer Nature - SN SciGraph project
206 rdf:type schema:Organization
207 Nfffd1afa66b04608a0d53d61fbc18a0e schema:volumeNumber 27
208 rdf:type schema:PublicationVolume
209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
210 schema:name Medical and Health Sciences
211 rdf:type schema:DefinedTerm
212 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
213 schema:name Oncology and Carcinogenesis
214 rdf:type schema:DefinedTerm
215 sg:journal.1094127 schema:issn 0724-4983
216 1433-8726
217 schema:name World Journal of Urology
218 schema:publisher Springer Nature
219 rdf:type schema:Periodical
220 sg:person.01007666002.23 schema:affiliation grid-institutes:grid.42505.36
221 schema:familyName Dorff
222 schema:givenName Tanya B.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007666002.23
224 rdf:type schema:Person
225 sg:person.01013134010.15 schema:affiliation grid-institutes:grid.42505.36
226 schema:familyName Quinn
227 schema:givenName David I.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15
229 rdf:type schema:Person
230 sg:person.010304735667.62 schema:affiliation grid-institutes:grid.42505.36
231 schema:familyName Tsao-Wei
232 schema:givenName Denice
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010304735667.62
234 rdf:type schema:Person
235 sg:person.0632606342.26 schema:affiliation grid-institutes:grid.42505.36
236 schema:familyName Miranda
237 schema:givenName Gus
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632606342.26
239 rdf:type schema:Person
240 sg:person.0757510711.79 schema:affiliation grid-institutes:grid.42505.36
241 schema:familyName Stein
242 schema:givenName John P.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757510711.79
244 rdf:type schema:Person
245 sg:person.0770566644.20 schema:affiliation grid-institutes:grid.42505.36
246 schema:familyName Skinner
247 schema:givenName Donald G.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770566644.20
249 rdf:type schema:Person
250 grid-institutes:grid.42505.36 schema:alternateName USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA
251 USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA
252 schema:name USC Keck School of Medicine, 1441 Eastlake Avenue, 90033, Los Angeles, CA, USA
253 USC Norris Cancer Center, 1441 Eastlake Ave., Room 3440, 90033, Los Angeles, CA, USA
254 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...